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Abstract
Background: The aim of this study was to investigate the influence of mild therapeutic hypothermia (MTH) on the
incidence of and recovery from acute kidney injury (AKI).
Methods: Patients who had undergone successful cardiopulmonary resuscitation (CPR) were included. Serum
creatinine and cystatin C were measured at baseline, daily up to 5 days and at ICU discharge. AKI was defined by
the Kidney Disease Improving Global Outcomes (KDIGO) criteria. MTH was applied for 24 h targeting a temperature
of 33 °C. Neurological outcome was assessed with the Cerebral Performance Categories score at hospital discharge.
Results: 126 patients were included in the study; 73 patients (58%) developed AKI. Patients treated with MTH had a
significantly lower incidence of AKI as compared to normothermia (NT) (44 vs. 69%; p = 0.004). Patients with less
favourable neurological outcomes had a significantly higher rate of AKI, although when treated with MTH the
occurrence of AKI was reduced (50 vs. 80%; p = 0.017). Furthermore, MTH treatment was accompanied by significantly
lower creatinine levels on day 0–1 and at ICU discharge (day 0: 1.12 (0.90–1.29) vs. 1.29 (1.00–1.52) mg/dl; p = 0.016) and
lower cystatin C levels on day 0–3 and at ICU discharge (day 0: 0.88 (0.77–1.10) vs. 1.29 (1.06–2.16) mg/l; p < 0.001).
Conclusions: Mild therapeutic hypothermia seems to have a protective effect against the development of AKI and on
renal recovery. This may be less pronounced in patients with a favourable neurological outcome.
Keywords: Acute kidney injury, Mild therapeutic hypothermia, Cardiopulmonary resuscitation, Neurological outcome,
Cystatin C, Creatinine
Background
The development of acute kidney injury (AKI) is associ-
ated with mortality rates ranging from 30 to 70%
although this depends on aetiology. AKI frequently com-
plicates out-of-hospital cardiac arrest (OHCA) with re-
ported rates between 12 and 40% [1, 2]. Moreover, after
OHCA severe forms of AKI are more common (AKI
stage 3 according to the Acute Kidney Injury Network
(AKIN) classification) and are associated with poorer
outcome [3]. Following successful resuscitation the
return of spontaneous circulation (ROSC) heralds a
complex pathophysiological process, the “post-cardiac
arrest syndrome” which comprises:
1. Post-cardiac arrest brain injury
2. Post-cardiac arrest myocardial dysfunction
3. Systemic ischaemia/reperfusion response
4. Persistent precipitating pathology [4, 5]
In particular, reperfusion injury after global ischaemia
leads to systemic inflammatory response syndrome with
consecutive tissue damage, also affecting the kidneys. In
a murine model of cardiopulmonary resuscitation (CPR)
there was significant infiltration of leukocytes in the kidneys
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and histomorphologic signs of AKI accompanied by ele-
vated creatinine and urea levels after cardiac arrest (CA)
[6]. A characteristic morphological injury pattern in renal
tissue, such as interstitial edema, renal tubular necrosis and
inflammatory cell infiltration, and elevated AKI biomarkers
such as neutrophil gelatinase-associated lipocalin (NGAL)
and cystatin C were observed in a swine model of AKI after
CA with ventricular fibrillation and asphyxiation [7].
Mild therapeutic hypothermia (MTH) is applied after
CPR to attenuate the consequences of post cardiac arrest
syndrome [4], but little is known about its influence on
renal function, renal pathophysiological processes and the
incidence of AKI. A previous study investigating renal
function after CPR reported delayed improvement of renal
function as determined by 4-h creatinine clearances dur-
ing treatment with MTH, but there were no significant
differences in serum creatinine levels or urinary output
when compared to treatment with normothermia [8]. A
meta-analysis of randomized controlled trials did not
demonstrate significant association between hypothermia
and the risk of AKI or the need for dialysis, although there
was positive correlation between lower target temperature
and rates of AKI [9]. Unfortunately these studies had only
small sample sizes and were performed before the estab-
lishment of the current Kidney Disease Improving Global
Outcomes (KDIGO) AKI classification.
The aim of our study was to investigate the incidence of
AKI in patients after successful CPR, using the KDIGO
classification [10] and to evaluate the influence of MTH
on AKI development and other indices of renal function.
Methods
This is a secondary analysis of our previously published
study investigating neurological outcome prediction of
secretoneurin after successful CPR [11]. This prospective
observational single-centre trial included consecutive
adult patients (age ≥ 18 years) admitted to the medical
intensive care unit (ICU) of the University Hospital of
Innsbruck from September 2008 to April 2013 after suc-
cessful CPR. Neuroendocrine tumour, stroke, intracra-
nial haemorrhage or trauma as the cause of cardiac
arrest or life expectancy of less than 24 h as determined
by the treating physicians were exclusion criteria.
Serum creatinine was measured at baseline, daily up to
5 days (day 0–4) and at ICU discharge. Serum cystatin C
was measured daily from day 0−4 and at ICU discharge.
The baseline creatinine values were determined based
on the following algorithm:
1. The median of all values available in the time range
between 6 months prior to admission and ending 6
days prior to enrolment was taken if at least five
values were available or if the number of values
available exceed the number available in the time
range starting 5 days prior to enrolment and ending
at enrolment or
2. Nadir value in the time range starting 5 days prior
to enrolment and ending at enrolment, if at least
one value was available or
3. Enrolment value, if the value is in normal range or
4. Value calculated by the modification of diet in renal
disease (MDRD) formula [12]
The occurrence of AKI was determined according to
the KDIGO guidelines, based on serum creatinine values
[10]. We could not apply urinary output criteria prop-
erly, because urinary output had not been recorded at
6-h intervals. We also documented the patients that re-
ceived renal replacement therapy (RRT). Patients were
excluded from the study if chronic renal insufficiency
(chronic kidney disease (CKD) > stage G3) was reported
in the medical history and no baseline creatinine meas-
urement was available. Patients receiving RRT were ex-
cluded from any further calculations involving creatinine
and cystatin C values.
Estimated glomerular filtration rate (eGFR) was calcu-
lated from creatinine and cystatin C values using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula respectively [13] at ICU discharge.
Sequential Organ Failure Assessment (SOFA), Acute
Physiology and Chronic Health Evaluation II (APACHE
II) scores and the use of catecholamines were docu-
mented at the day of ICU admission. Cardiac arrest data
such as the rate of bystander resuscitation, time to
ROSC and first monitored rhythm were collected from
the emergency or heart alarm protocol according to the
Utstein style [14]. Furthermore, it was documented if
patients underwent MTH using an intravascular cooling
device targeting a core body temperature of 33 °C
(measured in the urinary bladder) for 24 h. According to
the guidelines at study initiation MTH was routinely ap-
plied to comatose patients with an initially shockable
rhythm that had received advanced life support within
15 min and showed a ROSC within 60 min after col-
lapse. After modification of the European Society of
Cardiology (ESC) guidelines in 2010, MTH was also ap-
plied to comatose patients with an initially non-shockable
rhythm, if the event was observed and time to ROSC was
less than 25 min [15]. Neurological outcome was deter-
mined by the Cerebral Performance Categories Scale
(CPC) immediately before discharge either from hospital
or a long-term care facility, following a standardized
protocol [11].
The study protocol was approved by the Ethics
Committee of the Medical University of Innsbruck
(protocol number UN3493 272/4.31). Written informed
consent was obtained from next of kin or retrospectively
from patients who recovered.
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Statistical analysis
Categorical data are given as counts and percentages, con-
tinuous data as means and standard deviations or medians
with interquartile ranges. Normal distribution of continu-
ous data was checked by the Kolmogorov-Smirnov test.
As serum creatinine, cystatin C and most other variables
were not normally distributed, the Mann-Whitney U test
and the chi-square test were used for univariate compari-
son of categorical variables of neurological outcome,
normothermia (NT) and MTH treatment. A logistic re-
gression model was used to assess whether MTH treat-
ment is protective against AKI after adjustment for
clinical relevant variables such as SOFA score and time to
ROSC. The accuracy of serum creatinine and cystatin C
levels measured at day 0 in predicting AKI and neuro-
logical outcome was evaluated by receiver operating char-
acteristic (ROC) analysis. Mixed effects model analysis
was applied to evaluate the effect of MTH on creatinine
and cystatin C levels (day 0–4). For this analysis, creatin-
ine and cystatin C were logarithmically transformed to
achieve normally distributed values. P values < 0.05 were
considered statistically significant. IBM SPSS Statistics
(IBM Corp. Released 2012. IBM SPSS (Statistics for
Windows, Version 21.0. Armonk, NY, USA: IBM Corp.)
was used to analyse data.
Results
Patient characteristics
There were 126 patients included in this analysis [11]
(see Additional file 1): 55 patients were treated with
MTH. The mean duration of MTH at the target
temperature of 33 °C was 23.5 h (IQR 2.5) (3 h (IQR 2.0)
during cooling down, 13 h (IQR 3.0) during rewarming
and 34 h (IQR 23) during NT).
Patients treated with MTH were significantly younger
(60 vs. 67 years; p = 0.007), had a lower rate of
in-hospital cardiac arrest (4 vs. 17%; p = 0.019), a higher
rate of a shockable first monitored rhythm (87 vs. 38%;
p = 0.0001), a higher rate of vasopressor requirement
(95 vs. 68%; p = 0.0001) and a lower APACHE II score
(23 vs. 26; p = 0.0001) compared to those patients treated
with NT (see Additional file 2). A total of 64 of 126
patients (50.8%) had a poor neurological outcome
(CPC 3–5). Length of stay in the ICU (ICU-LOS) was
6 days (IQR 8). In patients with a favourable neuro-
logical outcome the length of stay was longer (8 days
(IQR 9) vs. 4 days (IQR 6)).
Acute kidney injury
A total of 73 of 126 patients (58%) developed AKI;
29 (40%) of them had AKI stage 3 including 20 (16%)
patients who received RRT. Patients who developed AKI
differed significantly by age, rate of bystander-initiated
CPR, time to ROSC, poor neurological outcome,
shockable first monitored rhythm, SOFA and APACHE II
score at admission and MTH treatment as compared to
patients without AKI (Table 1).
Patients treated with MTH (versus NT) had a signifi-
cantly lower incidence of AKI (44 vs. 69%; p = 0.004) and
a trend towards a reduced need for RRT (11 vs. 20%;
p = 0.201) (Table 2). Correspondingly, patients treated
with MTH had significantly lower creatinine levels on day
0 (1.12 (0.90–1.29) vs. 1.29 (1.00–1.52) mg/dl; p = 0.016),
day 1 and at ICU discharge (0.86 (0.66–1.02) vs. 1.14
(0.82–2.03) mg/dl; p = 0.001) and lower cystatin C levels
on day 0 (0.88 (0.77–1.10) vs. 1.29 (1.06–2.16) mg/l;
p < 0.001), day 1–3 and ICU discharge (1.06 (0.88–1.38)
vs. 1.66 (1.07–2.57) mg/l; p = 0.0001) as compared to pa-
tients treated with NT (Fig. 1).
The subgroup of patients with poor neurological out-
come had a significantly higher rate of AKI compared to
patients with favourable neurological outcome (70 vs.
45%; p = 0.004) (Fig. 2). Furthermore they had sig-
nificantly higher creatinine and cystatin C levels at
several time points during the observation period (see
Additional file 3).
In patients with a poor neurological outcome, further
analysis revealed a lower incidence of AKI in patients
treated with MTH as compared to NT (50 vs. 80%;
p = 0.017) (Table 2, Fig. 2). Correspondingly, these
patients had lower creatinine levels at ICU discharge and
significantly lower cystatin C levels on day 0–1 (day 0:
0.96 (0.83–1.30 vs. 1.44 (1.17–2.29) mg/l; p = 0.01) and at
Table 1 Patients characteristics in patients with or without
acute kidney injury (AKI)
No AKI
(n = 53)
AKI
(n = 73)
p value
Median age (IQR) 58 (18) 68 (20) 0.001
Female, n (%) 18 (33) 15 (21) ns
Bystander-initiated CPR, n (%) 43 (81) 41 (56) 0.003
Time to ROSC > 20 min, n (%) 22 (42) 49 (67) 0.004
Cardiac arrest in hospital, n (%) 5 (9) 9 (12) ns
Poor neurological outcome, n (%) 19 (36) 45 (62) 0.004
Favourable neurological outcome,
n (%)
34 (64) 28 (38) 0.004
Shockable first monitored rhythm,
n (%)
39 (74) 36 (49) 0.007
Catecholamines on admission, n (%) 39(74) 61 (84) ns
Baseline creatinine, MV ± SD (mg/dl) 0.95 ± 0.21 1.07 ± 0.97 ns
SOFA score, median (IQR) 9 (3) 11 (3) 0.0001
APACHE II score, median (IQR) 23 (6) 27 (7) 0.0001
MTH, n (%) 31 (58) 24 (33) 0.004
Abbreviations: CPR cardiopulmonary resuscitation, ROSC return of spontaneous
circulation, MV mean value, SOFA Sequential Organ Failure Assessment,
APACHE Acute Physiology and Chronic Health Evaluation, MTH mild
therapeutic hypothermia, ns not significant
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ICU discharge (1.13 (0.93–1.38 vs. 1.68 (1.17–2.48) mg/l;
p = 0.027) if treated with MTH (versus NT).
Patients with a favourable neurological outcome followed
a similar, but non-significant trend with lower rates of AKI
and RRT with MTH treatment (Table 2). Furthermore, they
had significantly lower creatinine on day 1 (0.82 (0.67–1.02)
vs. 1.03 (0.83–1.38) mg/dl; p = 0.049) and cystatin C
on day 0 (0.87 (0.76–1.06) vs. 1.14 (0.90–1.50) mg/l; p =
0.049) and day 1 (0.85 (0.73–1.23) vs. 1.17 (0.91–1.69)
mg/l; p = 0.023) if treated with MTH (versus NT).
Renal recovery
Renal function at ICU discharge was defined by eGFR, which
was significantly higher in patients treated with MTH versus
NT (eGFR creatinine, 83 (44) vs. 53 (55) ml/min/1.73 m2;
p = 0.0001; eGFR cystatin C, 71 (46) vs. 38 (51) ml/min/
1.73 m2; p = 0.0001) (see Additional file 4). Furthermore
we evaluated the need for RRT at hospital discharge: 20
patients received RRT, 11 of whom died in the ICU; 9
patients had need for RRT after CPR on the ICU, but none
of them had further requirement of RRT at hospital
discharge, which was after a median of 38 (27–66) days; 7
of them had a good neurological outcome.
Factors influencing occurrence of AKI and serum levels of
creatinine and cystatin C
In multivariate analysis mild therapeutic hypothermia re-
duced the risk of AKI and the SOFA score at admission
was the significant factor for the development of AKI
(Table 3). In the mixed model analysis we observed a
significant influence of MTH on creatinine and cystatin
C levels in the whole study population (p = 0.012 and
p < 0.0001, respectively).
In the subgroups we detected a statistically significant
effect of MTH on cystatin C levels in patients with good
neurological outcome (p < 0.0001) and on creatinine
Table 2 Number and percentages of patients with RRT and AKI
according to outcome and targeted temperature management
A
All patients
(n = 126)
Normothermia
(n = 71)
Hypothermia
(n = 55)
p value
AKI, n (%) 49 (69) 24 (44) 0.004
AKI 1, n (%) 21 (30) 11 (20)
AKI 2, n (%) 8 (11) 4 (7)
AKI 3, n (%) 20 (28) 9 (16)
RRT, n (%) 14 (20) 6 (11) ns
B
Favourable outcome
(n = 62)
Normothermia
(n = 27)
Hypothermia
(n = 35)
p value
AKI, n (%) 14 (52) 14 (40) ns
AKI 1, n (%) 5 (19) 8 (23)
AKI 2, n (%) 2 (7) 3 (9)
AKI 3, n (%) 7 (26) 3 (9)
RRT, n (%) 5 (19) 2 (6) ns
C
Poor outcome
(n = 64)
Normothermia
(n = 44)
Hypothermia
(n = 20)
p value
AKI, n (%) 35 (80) 10 (50) 0.017
AKI 1, n (%) 16 (36) 3 (15)
AKI 2, n (%) 6 (14) 1 (5)
AKI 3, n (%) 13 (30) 6 (30)
RRT, n (%) 9 (21) 4 (20) ns
Number (and percentages) of patients with continuous renal replacement
therapy (RRT) and Acute kidney injury (AKI) stage 1–3 and only stage 3
(Kidney Disease Improving Global Outcomes (KDIGO)) in all patients (A),
patients with good (B) and poor (C) neurological outcome treated with mild
therapeutic hypothermia or normothermia
ns not significant
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Fig. 1 Serum creatinine and cystatin C in patients treated with mild therapeutic hypothermia or normothermia. All patients: serum creatinine
(mg/dl) (a) and serum cystatin C (mg/l) (b) (mean and standard deviation) at day 0–4 and ICU discharge in patients treated with mild therapeutic
hypothermia or normothermia; *p < 0.05; **p < 0.01
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(p = 0.022) and cystatin C levels (p < 0.0001) in patients
with poor neurological outcome.
Prediction of AKI by creatinine and cystatin C
Serum creatinine values on admission reliably predicted the
development of AKI, with an AUC of 0.873 (0.813–0.933).
Similarly, for cystatin C levels on the day of admission the
AUC was 0.834 (0.735–0.934) for prediction of AKI.
Discussion
This is the first study investigating the influence of
MTH on the incidence of AKI after successful CPR
using the KDIGO criteria. In our population AKI
occurred less often in patients treated with MTH
compared to NT. This effect was more pronounced in
patients with a poor neurological outcome. There was
no significant difference in severe forms of AKI (stage 3)
and need for RRT. In the multivariate analysis the
protective effect of MTH on the development of AKI
remained significant.
Understandably, most studies have focused on hypoxic
brain injury following CA, but little is known about the
mechanisms that occur in the kidney leading to AKI
under these conditions [3]. Several animal studies of CA
have demonstrated that global ischaemia and a consecu-
tive post-CA syndrome result in significant functional
and morphological injury to the kidney [6, 7, 16–18].
Hypothermia may reduce the extent of focal damage after
isolated ischaemia/reflow injury (IRI) of the kidney as
shown in rat model of renal transplantation [19], but re-
ports on the renal effects of hypothermia in CA models
reflecting global ischaemic injury are lacking. Previous tri-
als on patients comparing the effect of MTH versus NT
provided conflicting results [20]. In a meta-analysis of 19
trials including patients with brain injury, OHCA or major
cardiovascular surgery with cardiopulmonary bypass, the
use of therapeutic hypothermia did not reduce the
incidence of AKI or the need for dialysis. However, a lower
target cooling temperature was associated with lower odds
of AKI and hypothermia was associated with lower
mortality [20].
In our study the MTH-treated population had reduced
incidence of AKI compared with the NT-treated popula-
tion. This was mainly related to mild forms of AKI. The
difference in severe forms of AKI (AKI 3) or require-
ment for RRT was not statistically significant. Since the
group of patients treated with MTH versus NT had sig-
nificant differences in their baseline characteristics a
sensitivity analysis was performed based on neurological
outcome, which may represent the most sensitive par-
ameter for the severity of hypoxic damage due to CA.
The beneficial effect of MTH with respect to rates of
AKI was highly significant in the patients with an un-
favourable neurological outcome. Though similar in
trend, the effect was less apparent in patients with a
favourable neurological outcome, which may be ex-
plained by the assumption that in patients with good
neurological outcome the duration of hypoxia and sever-
ity of post-CA syndrome was not pronounced enough to
contribute to significant renal damage. This is also
reflected by the fact that the overall rate of AKI was sig-
nificantly lower in patients with good neurological out-
come (i.e. 45 vs. 70%). Our results correspond well with
the data published by Hasper et al. [21] reporting that
AKI occurs in nearly 50% of patients with CA and
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Fig. 2 Acute kidney injury (AKI) after cardiopulmonary resuscitation (CPR). a Incidence of AKI in patients with good versus poor neurological
outcome. All patients: percentage of patients developing AKI or no AKI in each subgroup with good (n = 64) or poor neurological outcome
(n = 62); **p < 0.01. b Incidence of AKI in patients with poor neurological outcome treated with normothermia (NT) versus mild therapeutic
hypothermia (MTH). Patients with poor neurological outcome: percentage of patients developing AKI or no AKI when treated with MTH (n = 20)
or NT (n = 44); **p < 0.01
Table 3 Logistic regression analysis for the development of AKI
Odds ratio (95% CI) p value
Mild therapeutic hypothermia 0.424 (0.187–0.962) 0.040
SOFA score at admission 1.486 (1.211–1.824) 0.0001
Time to ROSC > 20 min 1.361 (0.577–3.209) 0.481
AKI acute kidney injury, SOFA Sequential Organ Failure Assessment,
ROSC return of spontaneous circulation
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patients with unfavourable neurological outcome are
affected more frequently. They also showed that changes
in serum creatinine observed over 24 h may contribute
to outcome prediction in patients post CA.
Our findings may be in accordance with published
data demonstrating that targeted temperature control in
kidney donors has a statistically and clinically significant
protective effect on renal-graft outcomes in recipients
[22]. The relative odds of delayed graft function were
38% lower when the kidneys were donated by patients
assigned to a targeted temperature of 34−35 °C than
when kidneys were donated by patients assigned to a
targeted temperature of 36.5−37.5 °C. Furthermore, renal
grafts from expanded-criteria donors and other high-risk
subgroups particularly benefited from hypothermia [22].
Though these data indicate that hypothermia may
attenuate the damage conferred by IRI to the kidney, it
is important to note that there is a distinct difference in
the pathophysiology of isolated renal IRI and AKI in the
setting of systemic injury conferred by CA and the
subsequent post-CA syndrome.
In our study we used cystatin C in addition to creatin-
ine to determine renal function during the first week
and at discharge to estimate renal recovery. Creatinine
with its well-known limitations in the acute setting is
still the standard measure of renal function, but has lim-
ited usefulness in the early detection of AKI [23]. The
serum concentration is greatly influenced by numerous
non-renal factors such as body weight, race, age, gender,
total body volume, drugs, muscle metabolism and pro-
tein intake [24, 25]. Therefore, it has to be considered
that estimation of eGFR based on serum creatinine
might overestimate renal function due to loss of muscle
mass in critically ill patients [26].
Cystatin C on the other hand is a low molecular-
weight cysteine proteinase produced by all nucleated
cells that is freely filtered through the glomerular mem-
brane and completely reabsorbed and metabolized by
the proximal tubular cells without secretion. In contrast
to creatinine, serum concentration of cystatin C is not
affected by inflammation, fever and/or outside agents or
by muscle mass, gender or age [27–29]. As such, it has
been proposed as an early biomarker of AKI in intensive
care [30, 31]. The KDIGO criteria rely on serum creatin-
ine and urine output as indicators of renal function. As
muscle metabolism is often impaired in a critically ill
patient, we might underestimate the occurrence of AKI
especially during MTH, when metabolic rates are de-
creased, but probably also under NT. Therefore we also
determined that cystatin C might be more sensitive for
smaller changes in renal function [32] and has been
shown to be strongly significantly correlated with the
histopathological grade of renal injury in an animal
model of ventricular fibrillation CA [33]. So far cystatin
C has not been described in the context of AKI and
MTH after CPR.
In the cohort treated with MTH the whole population
and the subgroup of patients with poor neurological out-
come had significantly lower creatinine levels than those
treated with normothermia. The same pattern was ob-
served for cystatin C levels independent of neurological
outcome. Both markers were significantly reduced at
several time points within 5 days after CPR in patients
treated with MTH. Whether this reflects improved renal
function or an altered production rate of the markers
cannot be discriminated by our approach. However, in a
sub study of the HACA trial, reduced creatinine clear-
ance was observed during MTH, whereas the respective
creatinine values tended to be even lower than those of
the patients treated with normothermia, indicating re-
duced creatinine production during MTH [8].
However, at ICU discharge creatinine and cystatin C
levels were still significantly lower in patients treated
with MTH. This corresponds to increased eGFRs, with
cystatin C-derived eGFRs consistently lower (ca. 20%)
compared to eGFRs based on serum creatinine. Since it
has previously been demonstrated that creatinine pro-
duction is diminished during longer ICU stays [26], the
eGFRs obtained from creatinine may overestimate renal
function at ICU discharge in our study. However, cysta-
tin C-derived eGFR also remained higher at ICU dis-
charge in the patients treated with MTH and this may
reflect improved renal recovery [34, 35]. Although renal
function at ICU discharge may not necessarily reflect
long-term renal function, the ICU LOS in patients with
good neurological outcome was 8 (IQR 9) days, which
would fit into the suggested observation period to evalu-
ate early renal recovery (7–90 days) [34, 36].
Limitations
There are several limitations of our study. First, this is a
single-centre study and allocation to MTH or NT was
not by randomization but according to recommenda-
tions at the time of the study. This might have led to
selection bias. However, we added MTH to the multi-
variate analyses and added a sensitivity analysis based on
neurological outcome to reduce such a bias.
Second, we only used the KDIGO criteria based on
creatinine values to determine AKI due to lack of prop-
erly recorded urinary output data. Third, we did not
measure creatinine clearance at discharge. To compen-
sate for that, we added cystatin C as an additional renal
functional parameter. Fourth, muscle metabolism and
production of creatinine might be impaired by lower
body temperature, which might lower its usefulness in
estimating renal function under treatment with MTH.
There are no data about the metabolism of cystatin C
during MTH. However, we saw good discrimination
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between MTH and NT later during the stay and at ICU
discharge, when MTH had already been stopped for a
prolonged time. Fifth, we have no data on long-term
outcome, but we can provide data on early renal recov-
ery by showing eGFR at ICU discharge and requirement
for RRT at hospital discharge.
Conclusions
In summary, these results indicate a moderate protective
effect of MTH on renal function after cardiac arrest and
possibly improved recovery from AKI. Although the effect
of MTH is more pronounced in mild forms of AKI, there
is still a significant effect in multivariate analysis. In this
context cystatin C seems to perform well as a biomarker to
determine renal function under application of MTH. Fur-
ther studies are needed to confirm these results.
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